Fluphenazine Decanoate

CHEMBL1200854 Phase 4 Zugelassen Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

591.8 g/mol

LogP

9.0

Phase

4

This long-acting injectable ester of fluphenazine is slowly released from the injection site over two to four weeks, providing sustained antipsychotic coverage. It is particularly useful for patients with schizophrenia who have difficulty adhering to daily oral medication.

Molekularmasse

591,8000 g/mol

LogP

9,00

TPSA

61,30 Å²

Lipinski-Regel der Fünf

Nicht bestanden

Therapeutische Bereiche

Schizophrenia Psoriasis

Wirkmechanismus

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

2D-Struktur

SVG PNG

Cite this structure

Embed this structure

SMILES

CCCCCCCCCC(=O)OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1

InChI

InChI=1S/C32H44F3N3O2S/c1-2-3-4-5-6-7-8-14-31(39)40-24-23-37-21-19-36(20-22-37)17-11-18-38-27-12-9-10-13-29(27)41-30-16-15-26(25-28(30)38)32(33,34)35/h9-10,12-13,15-16,25H,2-8,11,14,17-24H2,1H3

Molecular Formula

C32H44F3N3O2S

HBD / HBA

- / 9

Rotierbare Bindungen

16

Schwere Atome

41

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

This long-acting injectable ester of fluphenazine is slowly released from the injection site over two to four weeks, providing sustained antipsychotic coverage. It is particularly useful for patients with schizophrenia who have difficulty adhering to daily oral medication.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Fluphenazine Decanoate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200854. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 3388. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Suchen Sie patientenfreundliche Informationen?

Fluphenazine Decanoate auf PillFYI

Struktur

Schnelldaten

Formel: C32H44F3N3O2S

Externe Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.